December 17, 2018
Voyager Therapeutics Joins Michael J. Fox Foundation Initiatives and Education Campaigns to Accelerate the Development of New therapies and a Cure for Parkinson’s Disease |
December 10, 2018
Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease |
November 29, 2018
Voyager Therapeutics Enters into Strategic Manufacturing Collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies |
November 19, 2018
Voyager Therapeutics to Present at the Evercore ISI Healthcare Conference |
November 07, 2018
Voyager Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Highlights |
November 07, 2018
Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease |
October 31, 2018
Voyager Therapeutics to Host Third Quarter 2018 Financial Results and Corporate Highlights Conference Call |
October 16, 2018
Voyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy |
August 28, 2018
Voyager Therapeutics to Present at Investor Conferences in September |
August 07, 2018
Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights |
August 02, 2018
Voyager Therapeutics to Present at Investor Conferences in August |
July 31, 2018
Voyager Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Highlights Conference Call |
July 17, 2018
Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update |
June 28, 2018
Voyager Therapeutics Appoints Andre Turenne as President and Chief Executive Officer |
June 21, 2018
Voyager Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for VY-AADC for the Treatment of Parkinson’s Disease |
May 29, 2018
Voyager Therapeutics Announces Management Change |
May 18, 2018
Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting |
May 17, 2018
Voyager Therapeutics Announces New Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting |
May 10, 2018
Voyager Therapeutics Announces First Quarter 2018 Financial Results and Corporate Highlights |
April 30, 2018
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2018 Annual Meeting |
March 14, 2018
Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results |
March 09, 2018
Voyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson’s Disease |
February 27, 2018
Voyager Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results and Corporate Highlights Conference Call |
February 26, 2018
Voyager Therapeutics to Present at Cowen Health Care Conference |
February 20, 2018
Voyager Therapeutics and AbbVie Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative Diseases |
February 07, 2018
Voyager Therapeutics to Present at Leerink Partners Annual Global Healthcare Conference |
January 31, 2018
Voyager Therapeutics Announces CEO Succession Plan for 2018 |
January 23, 2018
Voyager Therapeutics Announces FDA Clearance of Investigational New Drug Application for VY-AADC for Advanced Parkinson’s Disease |
